Your browser is no longer supported. Please, upgrade your browser.
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E328.18 EPS (ttm)0.40 Insider Own0.60% Shs Outstand224.75M Perf Week-1.90%
Market Cap29.13B Forward P/E21.68 EPS next Y5.98 Insider Trans-2.65% Shs Float223.42M Perf Month-0.59%
Income90.00M PEG17.95 EPS next Q1.19 Inst Own98.40% Short Float2.56% Perf Quarter-13.82%
Sales2.82B P/S10.33 EPS this Y-79.50% Inst Trans-0.27% Short Ratio2.89 Perf Half Y-7.93%
Book/sh36.59 P/B3.54 EPS next Y28.64% ROA0.70% Target Price171.75 Perf Year-27.91%
Cash/sh5.25 P/C24.69 EPS next 5Y18.28% ROE1.10% 52W Range110.56 - 193.45 Perf YTD-32.04%
Dividend- P/FCF54.08 EPS past 5Y5.10% ROI1.60% 52W High-32.99% Beta1.08
Dividend %- Quick Ratio3.10 Sales past 5Y36.90% Gross Margin91.80% 52W Low17.25% ATR3.47
Employees2924 Current Ratio3.60 Sales Q/Q18.40% Oper. Margin21.70% RSI (14)48.15 Volatility3.24% 2.49%
OptionableYes Debt/Eq0.40 EPS Q/Q-38.80% Profit Margin3.20% Rel Volume0.53 Prev Close129.17
ShortableYes LT Debt/Eq0.39 EarningsJul 28 BMO Payout0.00% Avg Volume1.98M Price129.63
Recom1.90 SMA20-3.24% SMA501.75% SMA200-12.41% Volume1,055,465 Change0.36%
Jul-29-16Reiterated Stifel Buy $195 → $182
Jul-29-16Reiterated Barclays Equal Weight $165 → $150
Jul-13-16Reiterated SunTrust Buy $220 → $197
Jul-13-16Initiated RBC Capital Mkts Outperform $188
Jul-11-16Upgrade Credit Suisse Neutral → Outperform $186 → $165
Jun-27-16Upgrade Citigroup Neutral → Buy
May-09-16Reiterated Barclays Equal Weight $175 → $180
Mar-08-16Downgrade Robert W. Baird Outperform → Neutral $221 → $170
Feb-25-16Initiated Citigroup Buy $165
Feb-04-16Reiterated UBS Buy $222 → $200
Feb-04-16Reiterated Barclays Equal Weight $202 → $175
Jan-20-16Initiated Credit Suisse Neutral
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $225
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Dec-11-15Reiterated Stifel Buy $250 → $245
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-14-15Downgrade Barclays Overweight → Equal Weight $220 → $205
Sep-01-15Initiated Raymond James Strong Buy $225
Jul-31-15Reiterated UBS Buy $220 → $223
Jul-31-15Reiterated Stifel Buy $239 → $257
Aug-26-16 03:38PM  Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd
11:06AM  What Do Analysts Think about BioMarins Return Potential?
08:04AM  How Much Did BioMarins Lead Drug Vimizim Earn in 1H16?
Aug-25-16 09:35PM  Tesla Tops Forbes' 2016 List of Most Innovative Companies (TSLA, CRM) at Investopedia
09:04AM  Will Teva Pharmaceutical Strengthen Specialty Pipeline in 3Q16?
Aug-22-16 09:27AM  New Strong Sell Stocks for August 22nd
Aug-19-16 12:39PM  Biotech Stocks: Trouble Ahead, Trouble Behind? at
11:04AM  Horizons Orphan Drug Business Faces These Opportunities
Aug-18-16 06:29PM  Spiros Segalas on Alexion Pharmaceuticals
06:07PM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : August 18, 2016
11:10AM  What Are the Opportunities for Horizon in 2016?
Aug-15-16 07:37AM  New Strong Sell Stocks for August 15th
Aug-12-16 08:53AM  How to Play a Nasdaq Breakout
Aug-10-16 12:41PM  Are High Composite Ratings An Automatic 'Buy' Signal? No. Here's Why
Aug-09-16 10:49AM  Biotech Stocks: Blame Gilead? at
09:08AM  What Do Analysts Recommend for Regeneron after 2Q16 Earnings?
Aug-08-16 04:41PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events
09:05AM  What Are Analysts Recommending for Shire?
Aug-05-16 11:07AM  An Update on Shires Upcoming Milestones
07:22AM  New Strong Sell Stocks for August 5th
Aug-04-16 04:48PM  Whats behind Shires 2Q16 Earnings Surprise?
02:37PM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : August 4, 2016
Aug-03-16 11:34AM  Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
09:04AM  Update on Analyst Recommendations for Alexion
07:01AM  Biogen Is a Takeover Target but Don't Ignore the Risks
Aug-02-16 11:05AM  Analyst Recommendations for Vertex Pharmaceuticals after 2Q16 Earnings
09:59AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : August 2, 2016
09:08AM  Is BioMarin Set to Become Profitable in 2017?
09:05AM  How Significant Is Alexions Opportunity with Soliris?
09:05AM  How Vertex Is Strategizing to Continue Its Growth
Aug-01-16 05:05PM  What's Driving The Biotech Stock Rally? And Will It Last?
11:08AM  Strong Growth for Soliris in 2Q16
11:07AM  How Much Did Kalydeco Add to Vertexs Top Line?
09:09AM  Behind Alexions Updated Guidance for Its Metabolic Franchise
Jul-31-16 11:14AM  BioMarin: Why So Many Buy Recommendations?
Jul-29-16 04:13PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
02:26PM  Understanding Alexions 2Q16 Performance
02:26PM  Alexions 2Q16 Earnings Just Might Impress You
11:58AM  Biotech Stocks: The End of Political Risk? at
Jul-28-16 02:09PM  Short-Sellers Favor These 2 Biotech Stocks In July
01:37PM  Todays Trending Stocks: Pioneer, Ariad, Hershey, and 2 More at Insider Monkey
01:25PM  3 Big Drugmakers That Beat Wall Street Q2 Estimates Thursday
11:33AM  Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
09:22AM  Stocks to Watch: Facebook, GoPro, Raytheon, Thermo Fisher, Alexion at The Wall Street Journal
09:19AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
09:07AM  What to Expect from Shires Genetic Disease Franchise
08:17AM  Alexion misses 2Q profit forecasts
08:16AM  Pharma earnings roundup
08:15AM  Alexion (ALXN) Beats on Q2 Earnings and Revenues
07:07AM  Q2 2016 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open
06:30AM  Alexion Reports Second Quarter 2016 Results Business Wire
Jul-27-16 09:47AM  Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Jul-26-16 05:17PM  What Do Analysts Recommend for Shire?
03:00PM  [$$] Three Biotech Q2 Reports Hold Potential at
09:43AM  Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Jul-25-16 11:05AM  Understanding Improvement in Vertex Pharmaceuticalss PE Multiple
11:05AM  Whats behind the Recent Fall in Alexions Valuation Multiple?
09:05AM  Orkambi Launch Impacts Vertex Pharmaceuticalss Major Revenue Contributor
09:05AM  How Kanuma Addition to Alexions Portfolio Impacts Its Earnings
Jul-23-16 07:01AM  I Just Bought These 4 Fast-Growing Biotech Stocks at Motley Fool
Jul-22-16 01:16PM  Is Vertex Pharmaceuticals Exposed to Drug Pricing Risks?
01:16PM  How Alexion Plans to Fuel Strensiq Sales
01:16PM  How Can Alexion Stay ahead of the Competition with Soliris?
Jul-21-16 04:43PM  Wall Street Looks for Vertex Pharmaceuticals to Break Even in 2Q16
04:20PM  Sorry, You Can't Buy This Hot Biotech -- At Least Not Directly at Motley Fool
03:56PM  Analysts Gauge Alexion Pharmaceuticals Return Potential
03:54PM  Will Alexion Pharmaceuticals 2Q16 Earnings Surprise?
Jul-19-16 04:21PM  Earnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why at Motley Fool
Jul-15-16 04:19PM  Biotech: Steak, But No Sizzle at
Jul-14-16 11:07AM  Why Alexion Pharmaceuticals, Inc. Stock Sank 23.5% in June at Motley Fool
09:04AM  Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB) Business Wire
Jul-13-16 04:02PM  Amazon Target Primed; Top Banks Initiated Ahead Of Earnings
01:47PM  Alexion Pharmaceuticals (ALXN) Stock Gets Outperform Rating at RBC Capital
12:58PM  16 Recently Upgraded Stocks (APD,ALXN,ADP,BHI) at Investopedia
11:39AM  Biotech: 'We Would Not Be Surprised to See Volatility Continue' at
11:29AM  [$$] Three Biotech Picks With Pipeline Upside at
05:32AM  Coverage initiated on Alexion Pharma by RBC Capital Mkts
Jul-12-16 01:33PM  Stocks in record territory
10:10AM  Biotechs With Drug Pipelines Closest to Zero Valuation at 24/7 Wall St.
Jul-11-16 10:05AM  The Word on the Street: How Analysts See BioMarin Now
10:05AM  Why Did BioMarins Share Price Tank after Brexit?
10:00AM  Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016 Business Wire
09:22AM  Alexion (ALXN) Stock Gains on Ratings Upgrade
08:58AM  Coverage Initiated on Select Biotech Equities
08:50AM  Morning Movers: Alexion Pharma Gains on Upgrade; Alcoa Rises Ahead of Earnings at
08:15AM  Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More
01:05AM  A Look at Alexions 2016 Guidance
01:04AM  How Much Upside Potential Does Alexion Have?
Jul-07-16 10:41AM  Brexit Shouldn't Have Much, If Any, Effect on This Sector at Motley Fool
08:30AM  New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress Business Wire
Jul-06-16 11:16AM  Gilead Sciences: 'This Could Be One of the Strongest Quarters in Some Time' at
Jul-02-16 12:40PM  The 10 Worst-Performing S&P 500 Stocks in June
Jun-30-16 03:06PM  ALXN 1210: Another of Alexions Important Pipeline Drugs
Jun-29-16 02:24PM  Behind the Recent Fall in BioMarins Premium Valuation
02:06PM  What Are the Additional Labels for Alexions Soliris?
02:06PM  Why Did Alexion Fall after Brexit?
01:28PM  16 Biopharma Companies Besides Medivation That Are Attractive Targets
Jun-27-16 03:55PM  Why Did Alexions EV-to-EBITDA Multiple Nosedive?
03:55PM  Whats Behind Alexions Price-to-Earnings Premium?
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PARVEN ALVIN SDirectorAug 22Option Exercise18.0115,000270,15021,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 22Sale136.5315,0002,047,9506,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 15Sale135.5170094,8576,373Aug 24 05:33 PM
Carmichael ClareEVP, Chief HR OfficerAug 08Sale137.1416522,62839,577Aug 10 06:23 PM
Moriarty John BEVP & General CounselAug 08Sale137.1413518,51451,225Aug 10 06:23 PM
Sinha VikasEVP & CFOAug 08Sale137.1427737,988178,463Aug 10 06:23 PM
Wagner Heidi LSVP, Global Government AffairsAug 08Sale137.1422230,44532,115Aug 10 06:24 PM
BELL LEONARDDirectorAug 08Sale137.141,010138,511405,289Aug 10 06:22 PM
Hallal DavidCEOAug 08Sale137.1433245,530189,266Aug 10 06:22 PM
Moriarty John BEVP & General CounselJun 13Sale135.72918124,59151,360Jun 14 04:50 PM
MACKAY MARTINEVP & Global Head of R&DMay 16Sale139.204,097570,28442,688May 18 04:36 PM
Wagner Heidi LSVP, Global Government AffairsMay 13Sale138.65537,34832,337May 13 05:48 PM
O'Neill JulieEVP. Global OperationsMar 02Sale149.5565197,35736,034Mar 04 06:21 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 29Sale138.9132945,70116,886Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 29Sale138.91547,50141,579Mar 01 06:34 PM
BELL LEONARDDirectorFeb 29Sale138.923,995554,987742,197Mar 01 06:32 PM
Carmichael ClareEVP, Chief HR OfficerFeb 29Sale138.911,312182,25039,742Mar 01 06:32 PM
Moriarty John BEVP & General CounselFeb 29Sale138.911,201166,83352,278Mar 01 06:32 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 29Sale138.91905125,71443,799Mar 01 06:33 PM
Wagner Heidi LSVP, Global Government AffairsFeb 29Sale138.9154775,98432,390Mar 01 06:34 PM
Hallal DavidCEOFeb 29Sale138.932,014279,800191,012Mar 01 06:32 PM
Sinha VikasEVP & CFOFeb 29Sale138.911,122155,862178,740Mar 01 06:33 PM
MACKAY MARTINEVP & Global Head of R&DFeb 29Sale138.911,000138,91046,785Mar 01 06:34 PM
O'Neill JulieEVP. Global OperationsFeb 29Sale138.9166392,09736,685Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 16Sale143.4918726,83336,633Feb 18 06:29 PM
Hallal DavidCEOFeb 08Sale138.053,946544,763173,026Feb 08 07:57 PM
BELL LEONARDDirectorFeb 08Sale138.0911,4741,584,442746,192Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 08Sale138.052,665367,91134,054Feb 08 07:57 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 08Sale138.071,474203,51844,704Feb 08 07:56 PM
Moriarty John BEVP & General CounselFeb 08Sale138.082,633363,57748,501Feb 08 07:58 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale138.07942130,06629,937Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale138.07778107,41930,348Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 08Sale138.091,966271,48140,785Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 08Sale137.613,890535,316171,862Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 05Sale143.501,954280,404175,752Feb 08 07:56 PM
MACKAY MARTINEVP & Global Head of R&DFeb 05Sale141.562,005283,82342,751Feb 08 07:56 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale143.232,080297,91931,126Feb 08 07:55 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale143.14997142,70830,879Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 05Sale143.451,969282,44751,134Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 05Sale143.481,970282,66146,178Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 05Sale141.761,993282,53836,719Feb 08 07:57 PM
BELL LEONARDDirectorFeb 05Sale143.122,136305,702757,666Feb 08 07:56 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 05Sale143.021,051150,31414,215Feb 08 07:57 PM
Hallal DavidCEOFeb 05Sale141.636,722952,043176,972Feb 08 07:57 PM
Hallal DavidCEOFeb 04Sale143.8362990,469142,558Feb 08 07:57 PM
BELL LEONARDDirectorFeb 04Sale143.832,262325,338746,997Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale143.8420729,77426,949Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 04Sale143.8416924,30925,747Feb 08 07:57 PM
Sinha VikasEVP & CFOFeb 04Sale143.83703101,116165,943Feb 08 07:56 PM
BELL LEONARDDirectorDec 29Option Exercise22.9028,968663,367778,227Dec 29 05:03 PM
BELL LEONARDDirectorDec 29Sale190.8028,9685,526,983749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Option Exercise22.904009,160749,659Dec 29 05:03 PM
BELL LEONARDDirectorDec 28Sale190.1540076,060749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Option Exercise22.905,632128,973754,891Dec 29 05:03 PM
BELL LEONARDDirectorDec 24Sale190.005,6321,070,080749,259Dec 29 05:03 PM
BELL LEONARDDirectorDec 17Option Exercise22.9070,0001,603,000819,259Dec 21 05:43 PM
BELL LEONARDDirectorDec 17Sale187.6970,00013,137,985749,259Dec 21 05:43 PM
NORBY R DOUGLASDirectorDec 11Sale187.7145,4428,530,12432,481Dec 15 05:36 PM
Moriarty John BEVP & General CounselDec 11Sale182.73943172,31141,340Dec 15 05:35 PM
Veneman Ann MDirectorDec 11Sale187.48895167,7953,252Dec 15 05:36 PM
BELL LEONARDDirectorDec 11Sale187.5621,3193,998,527727,940Dec 15 05:36 PM
Islam SaqibEVP, Chief Strat & Port. Off.Dec 08Sale190.00950180,50036,385Dec 08 07:36 PM
BELL LEONARDDirectorDec 08Sale188.2070,00013,173,840849,088Dec 08 07:36 PM
BELL LEONARDDirectorNov 25Option Exercise22.9035,000801,500954,088Nov 30 05:42 PM
BELL LEONARDDirectorNov 25Sale181.8935,0006,366,288919,088Nov 30 05:42 PM
Thiel CarstenEVP, Chief Commercial OfficerNov 10Sale173.343,000520,02028,018Nov 12 06:25 PM
PARVEN ALVIN SDirectorNov 02Sale178.73895159,9634,645Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Nov 02Sale180.00975175,50037,335Nov 04 05:29 PM
BELL LEONARDDirectorNov 02Sale180.1235,0006,304,200919,088Nov 04 05:29 PM
Islam SaqibEVP, Chief Strat & Port. Off.Oct 26Sale168.441,558262,43038,310Oct 29 05:17 PM
Thiel CarstenSVP, EMEA & Asia PacificSep 10Sale169.18812137,37129,018Sep 10 08:45 PM
BELL LEONARDDirectorSep 09Sale180.101,050189,105919,088Sep 10 08:46 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale179.5536665,7156,464Sep 10 08:45 PM
O'Neill JulieEVP. Global OperationsSep 02Sale171.76647111,12921,443Sep 10 08:46 PM
Carmichael ClareEVP, Chief HR OfficerSep 01Sale168.6230551,42927,156Sep 03 07:08 PM